A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects With Spinocerebellar Ataxia

Trial Profile

A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects With Spinocerebellar Ataxia

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Trigriluzole (Primary)
  • Indications Spinocerebellar ataxias
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 07 Aug 2017 According to a Biohaven Pharmaceutical Holding Company media release, dosing of all patients has been commenced in this trial. Top-line results are now expected in the fourth quarter of 2017.
    • 12 Jul 2017 The results of this trial will also support regulatory filings in Europe and Japan according to a Portage Biotech media release.
    • 30 May 2017 According to a Biohaven Pharmaceutical media release, the company expects to submit an NDA to the FDA in early 2018 based on the results of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top